nafronyl has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kubatiev, AA | 1 |
| Balashova, TS | 1 |
| Smirnova, VIu | 1 |
| Strokov, IA | 1 |
| Konstantinovskaia, TA | 1 |
1 other study available for nafronyl and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[The effect of naftidrofuryl on peroxidation of serum and erythrocyte membrane lipids in patients with insulin-dependent diabetes mellitus].
Topics: Adult; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Erythrocyte Membrane; Female; Humans; Lipid | 1996 |